Genocea Biosciences Inc. buy Reibach111
Summary
This prediction ended on 03.06.19 with a price of €9.37. With a performance of 70.19% the BUY prediction by Reibach111 was a big success. Reibach111 has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -1.189% | -3.063% | 10.586% | 15.272% |
iShares Nasdaq 100 | 3.663% | 8.732% | 34.914% | 58.325% |
iShares Nikkei 225® | -1.422% | -0.414% | 3.883% | 4.190% |
iShares S&P 500 | 2.182% | 4.907% | 28.279% | 51.241% |
Comments by Reibach111 for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Reibach111 stimmt der Buy-Einschätzung von foxxone zu
Reibach111 stimmt am 13.03.2019 der Buy-Einschätzung von foxxone mit dem Kursziel 1$ zu.
Überschrift: Genocea Biosciences
Stopped prediction by Reibach111 for Genocea Biosciences Inc.
Genocea Biosciences Inc.
08.03.18
10.09.18
10.09.18